Roivant Sciences GMBH is launching its 13th subsidiary, or "vant," this time focused on the development of respiratory diseases. The new Respivant will focus initially on the development of a Phase II drug for chronic cough in patients with idiopathic pulmonary fibrosis.
The new unit’s announcement Sept
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?